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Equine herpesvirus-1 (EHV-1) is a member of Genus Varicellovirus,
Alphaherpesvirinae, Herpesviridae and possesses a linear double-stranded
DNA genome, ~150 kbp in length (O'Callaghan and Osterrieder, 2008;
Telford et al., 1992). During lytic replication, the viral gene program of
immediate-early, early, and late stages is governed by EHV-1 positive
and negative regulatory proteins (Caughman et al., 1985; Gray et al.,
1987a, b). The IE protein (IEP) upregulated by a tegument ETIF protein
(ETIFP) (Elliott and O'Hare, 1995) trans-activates early and some late
genes (Kim et al., 1997; Smith et al., 1992, 1994), and also downregulates
its own promoter (Kim et al., 1995). Early regulatory gene products in-
clude the EICP0 protein (IECP0P), IR4 protein (IR4P) and UL5 protein
(UL5P) that independently or synergistically with the IEP trans-activate
early and late genes (Bowles et al., 2000; Breitenbach et al., 2009; Holden
et al., 1995; Smith et al., 1992). In addition, three early EHV-1 gene prod-
ucts, the IR2 protein (IR2P) (Harty and O'Callaghan, 1991; Kim et al.,
2006), UL4 protein (UL4P) (Charvat et al., 2011), and IR3 RNA
(Ahn et al., 2007, 2010), play a role in regulating viral gene expression
as negative regulatory molecules.
EHV-1 persistent infection in either cell culture (Henry et al.,
1979) or an animal model (Campbell et al., 1976; O'Callaghan et al.,
1983) is mediated by virus enriched with EHV-1 defective interfering
particles (DIP) that have a genome composed of a unique IR4/UL5hybrid gene, the UL3 and UL4 genes of the parent virus, cleavage
and package signals, and an origin of replication (Baumann et al.,
1986, 1987; Ebner and O'Callaghan, 2006). Co-existence of both vi-
ruses may be maintained by a mechanism in which the IEP of the
standard virus trans-activates the three genes of the DIP genome
whose protein products downregulate expression of the IE gene and
temper virus gene expression (Chen et al., 1999). The IR4/UL5 hybrid
gene is important in mediating interference with the replication of
the standard virus (Ebner et al., 2008), and more recent work
revealed that the UL4 gene encodes an early protein that inhibits
gene expression controlled by both viral and heterologous promoters,
suggesting the possibility that this non-essential gene contributes to
the mechanism of persistent infection (Charvat et al., 2011). Very lit-
tle is known about the EHV-1 UL3 gene that is also conserved in the
DIP genome. An initial study mapped the 1.2 kb UL3 transcript and
identiﬁed cis-acting elements such as a tentative TATA box, a 325 nt
5′untranslated region (UTR), and an open reading frame (ORF) of
258 amino acids (Harty et al., 1991). A later report showed that UL3
encodes a ~33 kDa myristylated protein that is localized in the peri-
nuclear region of the cytoplasm of infected cells (Harty et al.,
1993a). UL3 homologues are present in varicella-zoster virus as the
non-essential ORF2 (Davison and Scott, 1986; Sato et al., 2002), bo-
vine herpesvirus 1 as the dispensable circ gene (Fraefel et al., 1993,
1994; Schwyzer et al., 2002), and Marek's disease virus as ORF71 of
unknown function (Izumiya et al., 2001), but a UL3 homolog is not
present in the genome of herpes simplex viruses 1 or 2. However, it
remains unknown how the UL3 gene is regulated, in which stages
the UL3 gene is expressed, whether the UL3 protein (UL3P) is a com-
ponent of the EHV-1 virion, and whether the UL3 gene contributes es-
sential functions for EHV-1 replication and pathogenesis. Here, we
21B.C. Ahn et al. / Virology 420 (2011) 20–31begin to address these questions about the UL3 gene and its role in
the lytic replication of EHV-1.
Results
The UL3 gene is trans-activated by the IEP
The promoter sequences of the UL3 gene of RacL11 are different from
those of the Ab4 EHV-1 UL3 gene because the RacL11 EHV-1 genome
lacks a part of the UL1 gene and an entire UL2 gene as shown in Fig. 1A
(Telford et al., 1992; Yalamanchili andO'Callaghan, 1990). Previous stud-
ies (Harty et al., 1993a) showed that the UL3 transcript contains a 325 nt
UTR and that the UL3 gene harbors the tentative TATA box sequences at
30–36 nt upstream of the transcription initiation site (Fig. 1B). To deter-
mine how the UL3 gene is regulated, we cloned different regions of the
UL3 promoter into the pGL3-basic vector (Fig. 1B) and determined the
promoter activity in luciferase reporter assays. Comparison of the UL3Fig. 1. The genomic location of the UL3 gene, UL3 reporter constructs, and the UL3 promote
genome lacks a part of the UL1 gene and the entire UL2 gene compared to that of Ab4 EHV-1
EHV-1 sequence. (B) The UL3 cis-acting elements and UL3 promoter regions cloned into pGL3
UL3 transcription initiation site (Tci) (+1). Different regions of the UL3 promoter were clone
promoter activities from the different promoter regions of the UL3 gene without the effectopromoter activities revealed that the pUL3(−777/-54)-Luc lacking a ten-
tative TATA box sequence showed no promoter activity (Fig. 1C, bar 4)
and that the pUL3(−342/+324)-Luc showed the highest promoter ac-
tivity (Fig. 1C, bar 3) such that this promoter was used for additional as-
says. To determine which EHV-1 regulatory proteins trans-activate the
UL3 gene, co-transfection assays were performed using the pUL3
(−342/+324)-Luc as a reporter vector and plasmids that express
EHV-1 regulatory proteins as an effector vector. Luciferase reporter as-
says using a single effector plasmid showed that the UL3 gene is strongly
trans-activated by only the IEP, but not by any other EHV-1 regulatory
protein (Fig. 2A). Assays in which pairs of EHV-1 regulatory proteins
were tested for the ability to trans-activate the UL3 promoter revealed
that none of the proteins acted synergistically to achieve promoter activ-
ity greater than that obtained by the IEP alone (Fig. 2B). Overall, the re-
sults in Fig. 2B were very similar to those obtained with other EHV-1
promoters in that the negative IR2 protein greatly inhibited trans-activa-
tionmediated by the IEP (Kim et al., 2006) and that the EICP0P exhibitedr activities. (A) The location of the UL3 gene in the EHV-1 UL region. The RacL11 EHV-1
. The numbers indicate the nucleotide distances in the EHV-1 genome based on the Ab4
-Basic vector for promoter assay. “+” and “−” indicate the nucleotide distance from the
d into the pGL3-Basic vector (Promega) as described in Materials and methods. (C) The
r vector. RLU (relative luciferase unit). Error bars indicate the standard deviation.
Fig. 2. The trans-activation of the UL3 promoter mediated by individual or pairs of EHV-1 regulatory proteins. For the luciferase reporter assays, pUL3(−342/+324)-Luc as the
reporter vector and vectors expressing EHV-1 regulatory proteins were co-transfected onto the RK13 cells in 24 well plates, and luciferase activities were determined as described
in Materials and methods. RLU (relative luciferase unit). Error bars indicate the standard deviation. (A) Trans-activation of the UL3 promoter by a single EHV-1 regulatory protein.
(B) Trans-activation of the UL3 promoter by a pair of EHV-1 regulatory proteins.
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promoter (Kim et al., 2003).
The EHV-1 UL3 is an early gene and encodes a tegument protein
An earlier study showed that UL3 is transcribed as a 1.2 kb polyade-
nylated RNA and mapped its transcription start site and termination
site, but assignment of the UL3 gene to a temporal class was not carriedFig. 3. Identiﬁcation of the UL3 RNA as an early transcript and detection of UL3P. (A) Det
inhibitors CHX and PAA. (B) Detection of the UL3P in RK13 cells infected with EHV-1 and t
blot as described in Materials and methods. Lane 1 (M) shows molecular weight markers.out. To this end, the UL3 RNA transcript was examined in EHV-1
infected RK13 cells treated with metabolic inhibitors, and RNA tran-
scripts representative of the immediate-early (IE), early (TK) and late
(gK) temporal classes were detected as controls. When protein synthe-
sis was inhibited by the addition of cycloheximide (CHX), the sole IE
RNA transcript, but not the UL3, early TK, or late gK transcripts, was
readily detected at 6 hours post infection (hpi) (Fig. 3A lane 3). In unin-
hibited infected cells, the UL3, IE and TK transcripts were present atection of the UL3 RNA transcript in EHV-1 infected RK13 cells treated with metabolic
ransfected with plasmids expressing the UL3 ORF. The UL3P was detected by western
23B.C. Ahn et al. / Virology 420 (2011) 20–316 hpi, but the late gK RNA was not detected. When EHV-1 infected cells
were treated with the viral DNA replication inhibitor phosphonoacetic
acid (PAA), RNA transcripts of the immediate-early gene, early TK
gene, and the UL3 gene were detected at 20 hpi (Fig. 3A lane 5), but
the true late gK transcript was not synthesized as expected. Transcripts
of all three gene classeswere readily detected at 20 hpi in cells not trea-
ted with inhibitors. Overall, these results clearly indicate that the UL3
gene is a member of the early temporal class.
The UL3 gene encodes a protein with a predicted size of 258 amino
acids that is detected in the perinuclear region of infected cells (Harty
et al., 1993a). A ~33 kDa UL3P was detected in cells transfected with a
UL3 ORF-expressing plasmid (Fig. 3B lane 3) and in cells infected with
RacL11 (Fig. 3B, lane 5), but not in mock-infected cells (Fig. 3B lane 2).
In addition, a ~60 kDa GFP-UL3 fusion protein was detected in cells
transfected with a plasmid expressing the GFP-UL3 fusion gene
(Fig. 3B, lane 4), conﬁrming that the UL3 gene encodes ~33 kDa
UL3P during EHV-1 infection. Additional analysis to examine whether
the UL3P is a structural protein showed that the ~33 kDa UL3P was
detected in puriﬁed EHV-1 virions (Fig. 4A, lane 4) and infected
RK13 cells (Fig. 4A, lane 3), but not in mock-infected cells (Fig. 4A,
lane 2).
To address the location of the UL3P within the EHV-1 virion, NP-40
treated puriﬁed virions were fractionated using a 15–50% sucrose gradi-
ent, and each fractionwas assayed for theUL3 protein. Both theUL3P and
thewell characterized ETIF tegument protein were detected in the same
bottom fraction (Fig. 4B, fraction 1)which is thenucleocapsid/tegument-
enriched fraction as shown previously (Lewis et al., 1997). The UL3Pwas
also detected in the top fraction which is the envelope-enriched fraction
(Fig. 4B), suggesting the possibility that the UL3P may be an envelope
protein. To exclude this possibility, immunoﬂuorescence staining assaysFig. 4. Detection of the UL3 protein as a virion protein. (A) Detection of the UL3P in puriﬁed
(B) Detection of the UL3P in fractionated EHV-1 virions. The puriﬁcation and fractionation of
and gD proteins were performed as described in Materials and methods. Puriﬁed EHV-1 vir
tion. Each fraction was assayed for the UL3 protein and ETIF protein by western blot analysis.
RK13 cells using (C) anti-EHV-1 gD polyclonal antibody or (D) anti-UL3P polyclonal antibod
anti-UL3P polyclonal antibody. In Figs. 4C, D, and E, the top panels (a and c) are contrast imwere performed using formalin ﬁxed EHV-1 infected RK13 cells and an-
tibodies to UL3P and EHV-1 glycoprotein D (anti-gDP) as described in
Materials and methods. If the UL3P were a viral envelope protein, the
UL3P would be expressed on the surface of the EHV-1 infected RK13
cell at late times after infection and would be detected by immunoﬂuo-
rescence staining. Anti-glycoprotein D antibodies detected the EHV-
1 gD envelope protein on the surface of EHV-1 infected RK13 cells as a
positive control (Fig. 4C, c and d), but not on mock-infected cells
(Fig. 4C, a and b). The UL3P was not detected either on surface-stained
mock-infected RK13 cells (Fig. 4D, a and b) or EHV-1 infected RK13
cells (Fig. 4D, c and d). To rule out the possibility that the failure to detect
theUL3P on the cell surfacemaybe due to poor expression of theUL3P or
the inability of the anti-UL3P antibody to bind to native UL3P, western
blot analysis of infected cell extracts and immunoﬂuorescence staining
of permeabilized infected RK13 cells were performed, respectively. The
UL3P was readily detected in infected RK13 cells, but not in mock-
infected RK13 cells (data not shown). In addition, anti-UL3P antibodies
detected the UL3P in permeabilized EHV-1 infected RK13 cells (Fig. 4E,
c and d), but not in permeabilized mock-infected RK13 cells (Fig. 4E, a
and b). These results indicate that the UL3P is a tegument protein and
also suggest that the UL3P may be associated with envelope protein(s)
of the EHV-1 virion.
The UL3 gene is dispensable for EHV-1 replication
To determine whether the UL3 gene is essential for EHV-1 replica-
tion, we constructed a UL3 gene deleted EHV-1 (vL11ΔUL3) by using
the GalK BAC technology as described in Materials and methods
(Warming et al., 2005). The replacement of the UL3 gene with the
GalK marker was conﬁrmed by PCR ampliﬁcation of the GalK markerEHV-1 virions by western blot analysis. Lane 1 (M) shows molecular weight markers.
EHV-1 virions, and detection of the UL3, ETIF (EHV-1-trans-inducing factor homologue)
ions were treated with NP-40 and fractionated by 15–50% sucrose gradient centrifuga-
(C and D) Immunoﬂuorescence surface staining of mocked infected and EHV-1 infected
y. (E) Immunoﬂuorescence staining of permeabilized EHV-1 infected RK13 cells using
ages of green ﬂuorescence (bottom panels b and d).
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er set) and right (Fig. 5C, P2 and P4 primer set) ﬂanking regions were
PCR-ampliﬁed from pL11ΔUL3-GalK (Fig. 5A, lanes 1 and 3), but not
from pRacL11 (Fig. 5A, lanes 2 and 4). DNA sequence analysis of the
PCR amplicons (data not shown) indicated that the UL3 gene was
completely replaced with the GalK marker. Next, to exclude the pos-
sibility that the GalK marker may affect the biology of the mutant
virus, the GalK marker of pL11ΔUL3-GalK was removed to construct
a UL3 deleted BAC plasmid (pL11ΔUL3). Also, the GalK insert was
replaced with the UL3 gene to construct a UL3 rescued BAC plasmid
(pL11ΔUL3R). As shown in Fig. 5B, a primer set (Fig. 5C, P5 and P2)
speciﬁc to the UL3 gene ﬂanking regions generated amplicons of the
expected sizes from the pL11ΔUL3-GalK (Fig. 5B, lane 1), pL11ΔUL3
(Fig. 5B, lane 2), and pL11ΔUL3R (Fig. 5B, lane 3). DNA sequence anal-
ysis of each of the amplicons validated the nature of each construct
(data not shown). Further, the deletion and rescue of the UL3 gene
were conﬁrmed by the BamHI digestion pattern and Southern blot
analyses. The BamHI digestion showed that the digestion pattern of
pL11ΔUL3-GalK (Fig. 6A, lane 2) and pL11ΔUL3 (Fig. 6A, lane 3) dif-
fered from those of pRacL11 (Fig. 6A, lane 1) and pL11ΔUL3R
(Fig. 6A, lane 4). Southern blot analyses using the BamHI digested
DNAs and probes speciﬁc to the UL3 gene and to the GalK marker
showed that the UL3 gene speciﬁc probe bound only to pRacL11Fig. 5. Conﬁrmation of the deletion of the UL3 gene by PCR analysis. The replacement of the
ampliﬁcation of the UL3 ﬂanking sequences by using primer sets speciﬁc to the UL3 ﬂanking
UL3 ﬂanking region to conﬁrm replacement of the pRacL11 UL3 gene with the GalK marke
respectively. Left ﬂanking region (lanes 1 and 2). Right ﬂanking region (lanes 3 and 4). (B) T
from the pL11ΔUL3-GalK and the recovery of the UL3 gene in pL11 ΔUL3R. The primer set
marker and UL3 ﬂanking regions. P and arrows indicate primer and primer directions, resp(Fig. 6B, lane 1) and pL11ΔUL3R (Fig. 6B, lane 4), but not to
pL11ΔUL3-GalK and pL11ΔUL3 (Fig. 6B, lanes 2 and 3, respectively),
and that the GalK marker speciﬁc probe bound only to pL11ΔUL3-
GalK (Fig. 6C, lane 2), but not to pRacL11, pL11ΔUL3, and pL11ΔUL3R
(Fig. 6C, lanes 1, 3, and 4, respectively). These results indicate that the
UL3 gene of pRacL11 was replaced with the GalK marker and that the
GalK marker was removed from pL11ΔUL3-GalK and replaced with
the UL3 gene. Once the UL3 gene was deleted from pRacL11 and re-
covered from the pL11ΔUL3-GalK, the UL3 null virus (vL11ΔUL3)
and UL3 rescued virus (vL11ΔUL3R) were generated by cotransfec-
tion of pL11ΔUL3 or pL11ΔUL3R, respectively, and the Us4 gene con-
taining plasmid into RK13 cells as described in Materials and
methods. The absence of the UL3 gene in vL11ΔUL3 and recovery of
the UL3 gene in vL11ΔUL3R were conﬁrmed by western blot analysis
using an anti-UL3P antibody. The anti-UL3P antibody detected a
~33 kDa UL3P in RK13 cells infected with RacL11 (Fig. 6D, lane 2)
and vL11ΔUL3R (Fig. 6D, lane 5). Also, a ~60 kDa GFP–UL3 fusion pro-
tein as a control was detected from the pGFP–UL3 plasmid trans-
fected RK13 cells (Fig. 6D, lane 4). However, the ~33 kDa UL3P was
not detected in RK13 cells infected with vL11ΔUL3 (Fig. 6D, lane 3),
indicating that the UL3 gene was successfully removed and that the
UL3 gene is not essential for the EHV-1 replication. The levels of IEP
expression during the course of infection were virtually identical inUL3 gene with the GalK marker and removal of the GalK marker were veriﬁed by PCR
region sequences as described in Materials and methods. (A) PCR ampliﬁcation of the
r. Primer sets were speciﬁc to the GalK marker and the UL3 ﬂanking region sequences,
he PCR ampliﬁcation of the UL3 ﬂanking regions to conﬁrm removal of the GalK marker
was speciﬁc to the UL3 ﬂanking region sequences. (C) The location of primers on GalK
ectively.
Fig. 6. Conﬁrmation of the UL3 gene deletion. (A) Comparison of the BamHI digestion pattern of the pRacL11, pL11ΔUL3-GalK, pL11ΔUL3, and pL11ΔUL3R. BamHI digested pRacL11,
pL11ΔUL3-GalK, pL11ΔUL3, and pL11ΔUL3R DNAs were separated on 0.3% agarose gels and visualized. (B and C) Conﬁrmation of the deletion of the UL3 gene and GalK marker by
Southern blot analysis. BamHI digested EHV-1 BAC DNAs were separated and transferred onto the positively charged membrane. Presence and absence of the UL3 gene and GalK
marker were determined by probes speciﬁc to the UL3 gene or GalK marker as described in Materials and methods. (D) Conﬁrmation of the absence of the UL3P in vL11ΔUL3
infected RK13 cells by western blot analysis. Whole cell lysates of plasmid transfected or virus-infected RK13 cells were separated on 10% SDS-PAGE, and the presence of the
UL3P was examined by western blot as described in Materials and methods. Lane 1 (M) shows molecular weight markers. (E) Comparison of the IE gene expression between
RacL11 and vL11ΔUL3R. The expression levels of the IEP in RK13 cells infected with RacL11 and vL11ΔUL3R were compared at 3, 6, and 12 hpi as described in Materials and
methods.
Fig. 7. The morphology of the RacL11, vL11ΔUL3R and vL11ΔUL3 plaques in RK13 cells. (A) Morphology of the RacL11, vL11ΔUL3R and vL11ΔUL3 plaques in RK13 cells at 5 days
post infection was determined as described in Materials and methods. (B) Relative plaque size comparison of the RacL11, vL11ΔUL3R and v11ΔUL3 in RK13 cells. Relative plaque
sizes were determined by using ImageJ Software, and the two-tailed Student's t test was used for data analysis. Error bars indicate the standard deviation.
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deletion and repair of the UL3 gene was successful without major al-
teration of genomic structure.
The vL11ΔUL3 exhibits host cell tropism, plaque size, and growth kinetics
similar to those of the parental virus
Next, the plaque morphology of vL11ΔUL3 on RK13 cell mono-
layers was examined. As shown in Fig. 7, the RacL11, vL11ΔUL3R,
and vL11ΔUL3 showed similar plaque morphology on RK13 cell
monolayers (Figs. 7A and B), and there was no signiﬁcant difference
in plaque size among the three viruses (each p valueN0.266). To as-
sess if the deletion of UL3 affected host range, the ability of
vL11ΔUL3 to replicate in LM, RK13, NBL-6, Vero, and HeLa cells was
examined. The vL11ΔUL3, like both the parental virus and the UL3 re-
vertant virus, was able to grow in cells of mouse, rabbit, equine, mon-
key, and human origin and replicated in all ﬁve cell types to maximal
titers that were similar to those of the parental and revertant viruses
(Fig. 8A). In addition, RacL11, vL11ΔUL3, and vL11ΔUL3R exhibited
similar growth kinetics in RK13 cells infected with viruses at moi of
2 or 0.2 (Fig. 8B), indicating that the deletion of the UL3 gene does
not affect the growth properties of EHV-1 in cell culture.
Deletion of the UL3 gene does not alter the EHV-1 gene program
Even though the vL11ΔUL3 lacking the UL3 gene showed host cell
tropism and growth kinetics similar to those of the parental virus, the
possibility existed that deletion of the UL3 gene may affect the EHV-1
gene program. To address this possibility, the expression of the EHV-1Fig. 8. Cell tropism and growth kinetics of ΔUL3 EHV-1. Error bars indicate the standard
deviation. (A) Viral titers of vL11ΔUL3, vL11ΔUL3R and RacL11 in LM, RK13, NBL-6,
Vero, or HeLa cells were determined at 3 days post infection as described in Materials
and methods. (B) Growth kinetics of vL11ΔUL3, vL11ΔUL3R and RacL11 in RK13 cells
infected at a moi of 0.2 or 2 were determined as described in Materials and methods.sole IE gene and representative early and late genes at different time
points of infection was compared in RK13 cells infected with parental
RacL11 virus and vL11ΔUL3. The IEP was detected at 3 hpi in both
RacL11 and vL11ΔUL3 infected RK13 cells, and IEP levels in both
RacL11 and vL11ΔUL3 infected cells were almost identical during
early and late stages of replication (Fig. 9A, panel a). Protein expres-
sion from three early regulatory genes (UL5, IR4, and EICP0) was
barely detected in RK13 cells infected with RacL11 or vL11ΔUL3 at
3 hpi, and the levels of these three proteins in both RacL11 and
vL11ΔUL3 infected cells were similar during early and late time
points of replication (Fig. 9A, panels b, c, and d). As expected, the
late gene product glycoprotein D was ﬁrst detected at 12 hpi
(Fig. 9A panel e, lanes 7 and 8), and the amount of gD in RacL11
and vL11ΔUL3 infected RK13 cells was similar. These results and
those of repeated experiments that yielded results virtually identical
to those in Fig. 9 suggest that the absence of the UL3 gene does not af-
fect the EHV-1 gene program in its transition from the immediate-
early to early to late stages.
UL3 is not essential for EHV-1 replication or virulence in the CBA
mouse model
To examine if the deletion of the UL3 gene affects EHV-1 replica-
tion or virulence in vivo, experiments in the well characterized CBA
model were performed as described in Materials and methods. As
shown in Fig. 10A, mice infected intranasally with vL11ΔUL3 exhib-
ited a rapid and major loss in body identical to losses observed in an-
imals infected with the highly pathogenic parental RacL11 or UL3
revertant virus, and all infected animals exhibited clinical signs of
lethargy, huddling, and rufﬂed fur. By three days post infection, loss
of total body weight for the three groups of infected mice was 25%,
and comparison of body weight to that of the uninfected mice
showed p values of b0.00001. There were no signiﬁcant differences
of body weight loss among the groups of mice infected with RacL11,
vL11ΔUL3, and vL11ΔUL3R (all p valuesN0.28). When considering
mortality of EHV-1 infected mice, mice infected with vL11ΔUL3
began to die rapidly as 6 of 9 infected mice died by 3 dpi, and all 9Fig. 9. Comparison of the expression of EHV-1 immediate early, early, and late proteins
in RK13 cells was performed by western blot analyses as described in Materials and
methods. Lane 1 is a protein marker, lane 2 is a mock-infected RK13 cell control,
lanes 3, 5 and 7 are RacL11 infected RK13 cells, and lanes 4, 6 and 8 are vL11ΔUL3
infected RK13 cells. GAPDH was used as the control protein. Panels “a” to “e” indicate
the immediate early protein, early UL5 protein, early IR4 protein, early EICP0 protein,
and late glycoprotein D, respectively.
Fig. 10. Body weight and survival portions of EHV-1 infected mice, and EHV-1 titers of lungs of sacriﬁced mice and mice that succumbed to infection. Animal experiments were
performed as described in Materials and methods. Mice were intranasally inoculated with 3×106 pfu of RacL11, vL11ΔUL3, or vL11ΔUL3R, or were mock infected, and body weight
was measured daily. Viral titers were examined at 2, 3, and 4 days post infection from lungs of live mice, and at the time of death from dead mice. Error bars indicate standard de-
viation. (A) Percentage change in body weight of mice infected with vL11ΔUL3 (n=12), RacL11 (n=12), vL11ΔUL3R (n=12), or mock (n=12). (B) Survival proportions of mice
infected with vL11ΔUL3 (n=9), RacL11 (n=9) and vL11ΔUL3R (n=9). (C) Virus titers of lungs of live mice infected with vL11ΔUL3 (n=3), vL11ΔUL3R (n=3), or RacL11
(n=3). Mice were sacriﬁced at 2, 3, 4 dpi. (D) Virus titers of lungs of mice that succumbed to infection. Each bar indicates the average lung viral titer of dead mice at the same
day. The numbers of dead mice are n=6 (bar 1), n=2 (bar 2), n=4 (bar 3), n=3 (bar 4), n=4 (bar 5), n=2 (bar 6), and n=1 (bar 7), n=1 (bar 8), and n=1 (bar 9).
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mice infected with RacL11 died at 3 dpi, and 7 of the 9 (77%) mice
died by 7 dpi. Two of 9 mice infected with vL11ΔUL3R died at 3 dpi,
and 8 of the 9 (88%) mice died by 7 dpi. Also, percent survival data
of mice infected with vL11ΔUL3 was not signiﬁcantly different from
those of mice infected with RacL11 or vL11ΔUL3R (p valuesN0.31).
To determine whether the viral load differed among the three groups
of infected mice, viral titers in the lungs harvested from live and dead
mice were examined. The viral titers of lungs harvested from live
mice at days 2, 3, and 4 post infection were similar among the three
groups (Fig. 10C), and the viral titers of lungs of mice that succumbed
to infection also did not differ among the groups (Fig. 10D). Overall,
the results of all animal experiments revealed that the UL3 gene is
not required for EHV-1 replication or virulence in the CBA mouse
model.
Discussion
The EHV-1 UL3 gene that encodes a ~33 kDa myristylated cyto-
plasmic protein (Harty et al., 1993a) is one of only three genes that
comprise the genome of EHV-1 defective interfering particles (DIP)
that mediate EHV-1 persistent infection (Chen et al., 1996, 1999;
Ebner and O'Callaghan, 2006; Ebner et al., 2008; Harty et al.,
1993b). The IE protein encoded by the standard virus present in
EHV-1 preparations enriched for DIP activates expression of the
three DIP genes, UL3, UL4, and IR4/UL5 hybrid, resulting in high levels
of the UL3, UL4 and hybrid proteins that mediate interference withstandard virus replication. Studies with recombinant DIP that repli-
cate faithfully and can mediate persistent infection revealed the spe-
ciﬁc domains of the hybrid protein that are important for DIP
interference activity (Ebner et al., 2008). Deletion of the UL3 gene
that is perfectly conserved in the DIP genome leads to a markedly re-
duced ability of the DIP to interfere with standard virus replication in
cell culture (Ebner et al., 2008). As discussed below, the UL3 protein
downregulates EHV-1 promoters, an observation consistent with
the ﬁnding that high level expression of UL3 in DIP-infected cells
leads to reduction in standard virus replication. Also, recent experi-
ments to characterize the properties of the UL4 gene have shown
that the early UL4 protein can enter the nucleus and has a broad in-
hibitory function, suggesting its potential role in DIP-mediated inter-
ference and/or persistent infection (Charvat et al., 2011).
These recent observations about the UL4 gene suggest the possi-
bility that the poorly characterized UL3 gene may play a role in
EHV-1 gene regulation and contribute to the biological functions of
EHV-1 DIP. Here, we initiated studies to deﬁne basic aspects of the
regulation and expression of the UL3 gene and showed that its ex-
pression is governed by the sole IE protein and that experiments
with metabolic inhibitors deﬁnitively assigned UL3 to the early gene
class. Western blot analysis using puriﬁed EHV-1 virions revealed
that the UL3P is a component of the EHV-1 virion, and detection of
the UL3P from both the soluble material and insoluble pellet of
EHV-1 infected cells (data not shown) suggests that the UL3P is read-
ily solubilized. A similar observation that the circ protein of bovine
herpesvirus 1, the UL3P homologue, is a virion component was
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1 virions revealed that the UL3P colocalized with the ETIF protein,
suggesting that the UL3 protein is a tegument component. However,
following sucrose gradient fractionation of NP-40 disrupted virions,
a signiﬁcant portion of the UL3P was also detected in the envelope-
rich top fraction, but the UL3P was not detected on the surface of
EHV-1 infected RK13 cells by immunoﬂuorescence staining. In addi-
tion, plaque reduction assays revealed that anti-UL3P antibody
could not neutralize EHV-1 (data not shown). These results and the
fact that the protein is myristylated may indicate that the UL3P lies
within the outer portion of the tegument such that it associates
with envelope protein(s), but the UL3P is not an envelope protein.
Examination of the growth properties of an UL3 null virus
(vL11ΔUL3) generated by BAC technology clearly showed that the
UL3 gene is dispensable for EHV-1 replication in cell culture and
that UL3 does not contribute to the broad host range of this equine
pathogen. The UL3 deleted virus like the parental and UL3 revertant
viruses was capable of high titer replication in cells of mouse, rabbit,
equine, primate, and human origin. The UL3 null virus was also capa-
ble of high titer replication in the CBA mouse model and exhibited
pathogenic properties of the parent virus such that 100% of mice
infected with VL11ΔUL3 succumbed to infection by 4 days post infec-
tion. Thus, EHV-1 deleted of UL3 exhibited many of the biological
properties of the recently characterized UL4 null virus (Charvat
et al., 2011), indicating that these two genes that are conserved in
the DIP genome do not contribute functions essential for EHV-1
growth in cell culture or pathogenicity in the mouse model, even
though we cannot exclude the possibility that the UL3 gene may
play a role in EHV-1 infection of the horse. Unexpectedly, luciferase
reporter assays employing a variety of EHV-1 promoters and heterol-
ogous promoters of other viruses and cellular genes showed that the
UL4 protein has a broad inhibitory function (Charvat et al., 2011) that
may be due to its ability to bind some cellular general transcription
factors. Ongoing experiments employing similar reporter assays
have also shown that the UL3P downregulates luciferase activity
under the control of either EHV-1 promoters or promoters of cellular
genes. Also, preliminary ﬁndings from in vitro protein–protein inter-
active assays revealed that the UL3P binds cellular TATA box binding
protein (TBP) in an in vitro interaction assay (unpublished data).
These preliminary data suggest that both the UL3 and UL4 proteins
contribute functions that may temper EHV-1 gene expression and
contribute to the ability of defective interfering particles to interfere
with standard virus such that persistent infection can develop.
Whether these functions mediated in vitro by the UL3P are essential
aspects of DIP mediated persistent infection is a topic now under in-
vestigation in our laboratory.
Materials and methods
Cell culture and viruses
The LM, RK13, equine NBL-6, Vero, and HeLa cells used for viral
propagation were maintained with Eagle's minimal medium supple-
mented with 100 units of penicillin/ml, 100 μg of streptomycin/ml,
nonessential amino acids, and 5% (or 10%) fetal bovine serum. Patho-
genic RacL11 EHV-1 was used as the wild type EHV-1 (Hubert et al.,
1996).
Puriﬁcation and fractionation of EHV-1 virions
Highly puriﬁed EHV-1 virions were prepared according to previ-
ous methods (O'Callaghan and Randall, 1976; Perdue et al., 1974)
and fractionated using a modiﬁed method of Murphy et al. (2008).
100 μl of puriﬁed EHV-1 virions were mixed with 1 μl NP-40 followed
by incubation at 4 °C for 30 min. NP-40 treated virions were placed on
the top of a microfuge tube that contains 500 μl of 50% sucrose in thebottom and then 500 μl of 15% sucrose on the top followed by centri-
fugation at 14 K rpm at 4 °C for 2 h. Five 200 μl fractions were collect-
ed from the top to the bottom, and the presence of the UL3P in each
fraction was assessed by western blot analysis.
Construction of plasmids
PCR products were ampliﬁed using Accuprime pfx polymerase
(Invitrogen, Carlsbad, CA), pRacL11 EHV-1 BAC (pRacL11) template,
and proper primers. PCR products were digested with appropriate re-
striction enzymes and cloned into proper vectors using standard
cloning methods (Sambrook et al., 1989). All clones were conﬁrmed
by sequence analysis. Primer designs were based on the published se-
quences (Yalamanchili et al., 1991; Telford et al., 1992). The PCR
product of the UL3 ORF (primers, 5′ ttt gaa ttc gcc acc atg ggg gcc
tgc tgc tcc tct ag 3′, 5′ tta tgt aca att cag acc gta tat ggt gtt ttg c 3′)
was digested with EcoRI and BsrGI, and cloned into pEGFP-N1 (BD
Biosciences, San Jose, CA) digested with EcoRI and BsrGI (named
pCMV–UL3). For the GFP–UL3 fusion gene construction, the PCR
product of the UL3 gene (primers, 5′ ttt ctg tac aag acg cgt atg ggg
gcc tgc tgc tcc tct aga cgc 3′, 5′ ttt gcg gcc gct act agt att cag acc gta
tat ggt gtt ttg c 3′) was digested with BsrGI and NotI, and cloned
into pEGFP-N1 (BD Bioscience) digested with BsrGI and NotI
(named pGFP–UL3). To characterize the promoter of the UL3 gene,
the UL3 promoter region was PCR-ampliﬁed. PCR products of UL3
(−777/+324) (primers, 5′ tta ggt acc act gct atg ctg ggg ctc act g
3′, 5′ tat aga tct tag tac gtg cgt cac acc g 3′), UL3(−777/+225)
(primers, tta ggt acc act gct atg ctg ggg ctc act g 3′, 5′ tta aga tct atg
ttg gtt aca ggg gtg 3′), UL3(−342/+324) (primers, 5′ ata ggt acc
aca cag tct ttt aac acc atg 3′, 5′ tta aga tct atg ttg gtt aca ggg gtg 3′),
and UL3(−777/−54) (primers, 5′ tta ggt acc act gct atg ctg ggg ctc
act g 3′, 5′ tta aga tct agg agc cca atg gaa aaa ag 3′) were digested
with KpnI and BglII, and then cloned into pGL3-Basic (Promega, Mad-
ison, WI) digested with KpnI and BglII, respectively (named pUL3
(−777/+324)-Luc, pUL3(−777/+225)-Luc, pUL3(−342/+324)-
Luc, and pUL3(−777/−54)-Luc).
Luciferase reporter assays
Luciferase reporter assays were performed as previously described
(Ahn et al., 2007). Brieﬂy, 80% conﬂuent RK13 cells were prepared in
24 well plates, and 0.5 pM of reporter vector and 1 pM of effector vector
were used for cotransfection. Reporter vectors were pUL3(−777/
+324)-Luc, pUL3(−777/+225)-Luc, pUL3(−342/+324)-Luc, and
pUL3(−777/−54)-Luc. The effector vectors expressing EHV-1 regulato-
ry proteins were pIE, pIR2, pEICP0, pIR4, pUL5, and pETIF (Ahn et al.,
2007) as well as pCMV–UL3. Six micro litters of lipofectin (Invitrogen)
weremixedwith 100 μl of Opti-MEMmedium(Gibco, BRL, Gaithersburg,
MD), and incubated for 45 min at room temperature. Effector and report-
er plasmids were mixed with 100 μl of Opti-MEMmedium (Gibco, BRL),
and total DNAs were adjusted to the same amount with the pSVSPORT1
DNA (Gibco, BRL). The mixture was combined and incubated at room
temperature for 15 min, and 460 μl of Opti-MEM medium (Gibco, BRL)
was added. One-third of the total mixture was transferred into each of
three wells of a 24 well plate of RK13 cells after washing with serum-
and antibiotics-free E-MEM. At 8 hours post transfection (hpt), normal
growth medium was added, and luciferase activities were measured at
48 hpt using a luciferase assay kit (Promega) and a POLARstar OPTIMA
plate reader (BMG LABTECH Inc., Cary, NC) according to the manufac-
turer's directions.
Metabolic inhibitor treatment of EHV-1 infected RK13 cells and isolation
of RNA transcripts
Metabolic inhibition in virus-infected RK13 cells was performed as
previously described (Caughman et al., 1985; Gray et al., 1987b;
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with EHV-1 at moi of 5 and incubated at 37 °C in the presence of
the protein synthesis inhibitor cycloheximide (CHX, 100 μg/ml)
(Sigma-Aldrich Corp. St. Louis, MO) for 6 hours, or in the presence
of the viral DNA replication inhibitor phosphonoacetic acid (PAA,
200 μg/ml) (Sigma-Aldrich Corp.) for 20 h followed by isolation of
total RNA using a RNA Easy Kit (Qiagen, Valencia, CA). RNA tran-
scripts were detected by northern blot assays using total RNA and
probes speciﬁc to each RNA transcript.
Immunoﬂuorescence staining
90% conﬂuent RK13 cells were mock infected or infected with
EHV-1 at moi of 5 for 2 h at 4 °C, and incubated at 37 °C for 3 h. The
cells were trypsinized and split into a 6 well plate including a cover
slide at each well followed by additional 6 hours incubation. RK13
cells were ﬁxed with 4% paraformaldehyde/PBS for 20 min or 0.2%
Triton X 100 for 5 min and washed with PBS. Goat serum (Sigma-
Aldrich, 1:100 dilution in PBS) was added, and the slides were incubat-
ed at 37 °C for 1 h followed by ﬁve PBS washes for 5 min each. Primary
antibodies [anti-UL3P or anti-gDP antibodies (1:100 in PBS)] were
added onto goat serum treated RK13 cells and incubated at 37 °C for
1 h followed by ﬁve PBS washes for 5 min each. An anti-rabbit IgG
FITC conjugate (Sigma-Aldrich, 1:100 dilution in PBS) was added, and
the slides were incubated at 37 °C for 1 h followed by ﬁve PBS washes.
The slides were viewed on a Nikon Eclipse TE300 ﬂuorescent micro-
scope (Melville, NY).
Generation of vL11ΔIR3
To construct a vL11ΔUL3 lacking the UL3 gene, GalK BAC technol-
ogy was used as previously described (Ahn et al., 2010; Warming
et al., 2005). The plasmid pRacL11 EHV-1 BAC (named pRacL11)
(Rudolph et al., 2002) was transformed into SW106 E. coli. The puri-
ﬁed PCR product of the GalK marker harboring the EHV-1 UL3 gene
ﬂanking sequence (primers, 5′ agg ttt ccg ccg tgc ctg gtg tcg agg gcc
cac ccc tgt aac caa cat cg/cct gtt gac aat taa tca tcg gca 3′/5′ cgc cag
cga gaa aat aaa cga taa att cag acc gta tat ggt gtt ttg ctt ttt att taa/tca
gca ctg tcc tgc tcc tt 3′) was transformed into SW106 cells containing
the pRacL11. Positive colonies were selected on Gal positive selection
agar plates and conﬁrmed by PCR ampliﬁcation (primers, 5′ tga aac
atc tgc aac tgc gta aca aca gct tcg g 3′/5′ gtt aca gca gcg act gca agc
tgg 3′; 5′ atg atc ccg cag tta cag cct aca aac tgg 3′/5′ att ggt acc tcc
gat cag cac cag aat ctg 3′) of the EHV-1 UL3 gene ﬂanking regions
(named pL11ΔUL3-GalK). To remove the GalK marker from
pL11ΔUL3-GalK, counter selection was performed. Both ﬂanking re-
gions of the UL3 gene were combined by multiple rounds of PCR am-
pliﬁcation (left ﬂanking region primers, 5′ cta act tta ctc aac caa caa
ccc tgg 3′/5′ atg ata ctg acg atg ttg gtt aca ggg gtg ggc 3′; right ﬂanking
region primers, 5′ cgt cag tat cat aag caa aac acc ata tac ggt ctg 3′/5′ gtt
aca gca gcg act gca agc tgg 3′, combined ﬂanking region primers, 5′ cta
act tta ctc aac caa caa ccc tgg 3′/5′ gtt aca gca gcg act gca agc tgg 3′).
The puriﬁed UL3 ﬂanking region PCR DNA was transfected into
SW106 cells containing the pL11ΔUL3-GalK and positive colonies
were selected on Gal counter selection plates. Positive colonies
(named pL11ΔUL3) were conﬁrmed by PCR ampliﬁcation (primers,
5′ gtt aca gca gcg act gca agc tgg 3′/5′ tta ggt acc act gct atg ctg ggg
ctc act g 3′), sequence analysis of ampliﬁed PCR amplicons, BamHI di-
gestion, and southern blot analysis. To generate EHV-1 lacking the
UL3 gene, the puriﬁed pL11ΔUL3 and the Us4 gene containing plas-
mid were co-transfected into 80% conﬂuent RK13 cells by using a
BD CalPhos Mammalian transfection kit (Clontech, Mountain View,
CA) according to the manufacturer's directions. Supernatants were
harvested at 3 days post transfection (dpt), and the mutant virus
was screened by plaque puriﬁcation. Plaques lacking green ﬂuores-
cence were selected and puriﬁed by three rounds of plaque assays(named vL11ΔUL3). To generate the UL3 gene rescued EHV-1 from
pL11ΔUL3-GalK, the PCR product harboring the UL3 gene and its
ﬂanking sequences (primers, 5′ gtt aca gca gcg act gca agc tgg 3′/5′
cta act tta ctc aac caa caa ccc tgg 3′) was transfected into SW106 E.
coli harboring pL11ΔUL3-GalK. The replacement of the GalK marker
with the UL3 gene was conﬁrmed, and the UL3 gene rescued EHV-1
was generated (named vL11ΔUL3R) as described above.Southern, northern, and western blot analyses
To conﬁrm replacement of the UL3 gene of pRacL11 with the GalK
marker, removal of the GalK marker of pL11ΔUL3-GalK, and replace-
ment of the GalK marker of pL11ΔUL3-GalK with the UL3 gene,
BamHI digested pRacL11, pL11ΔUL3-GalK, pL11ΔUL3 and
pL11ΔUL3R DNAs were separated on a 0.3% agarose gel, and trans-
ferred onto a positively charged nylon membrane (Ambion, Austin,
TX) by using a semi-dry electroblotter (Bio-Rad Laboratories, Hercu-
les, CA). The DNA transferred membrane was placed on a piece of
blot paper saturated with 0.5 M NaOH for 15 min, brieﬂy washed
with 2×SSC, and baked at 80 °C for 1 h. The PCR amplicon of the
GalK marker (primers, 5′ cct gtt gac aat taa tca tcg gca tag 3′/5′ act
gtc ctg ctc ctt gtg atg g 3′) and the UL3 gene (primers, 5′ aca aaa tta
cct acg cca act ctg cga acg 3′/5′ gct tct gcg tag att tga taa cct cag agg
3′) were end-labeled with [γ-32P]ATP (New England Nuclear Corpo-
ration, Boston, MA) by T4 polynucleotide kinase (Promega) according
to the manufacturer's directions, respectively. The radiolabeled probe
was denatured by adding 1/10 volume of 3 M NaOH for 10 min at
room temperature and then neutralized by adding an equal volume
of 1 M Tris–HCl (pH 7). Prehybridization, hybridization, and washing
were performed using the NorthernMax Kit (Ambion) followed by
autoradiography using a phosphor image screen and the molecular
imager FX system (Bio-Rad Laboratories).
To detect the RNA transcripts of the UL3, IE, gK and TK genes, total
RNAs from metabolic inhibitor treated RK13 cells were separated on
5% urea gels and transferred onto a positively charged nylon mem-
brane (Ambion, Austin, TX) by using a semi-dry electroblotter (Bio-
Rad Laboratories) followed by baking of the RNA transferred mem-
brane at 80 °C for 1 h. Probes speciﬁc to RNA transcripts were pre-
pared from the PCR amplicons of the UL3 gene (primers, 5′ aca aaa
tta cct acg cca act ctg cga acg 3′/5′ gct tct gcg tag att tga taa cct cag
agg 3′), IE gene (primers, 5′ ctc tac gac ttc atc gag agc aac gac ttc
3′/5′ tcg ggc ctc tcc agc gtc ttg gcc aga ttg 3′), gK gene (primers, 5′
tta gga cga gaa gga ctc gcc caa taa gcc 3′/5′ cct atg ccg cgt tta cct tct
ggt ata ccc 3′) and TK gene (primers, 5′ gcc ggt cag gcg gca agt aac
aat agt tag 3′/5′ gag ggt gct gct cat gag ggg tat tag aga 3′), and the
northern blot was performed as described above.
For protein detection, 90% conﬂuent RK13 cells were infected with
RacL11, vL11ΔUL3, or vL11ΔUL3R at moi of 10, and virus-infected
RK13 cells were harvested at 3, 6, and 12 hpi. pCMV–UL3 and pGFP–
UL3 plasmids were transfected into the 90% conﬂuent RK13 cells by
using Lipofectin (Invitrogen) according to the manufacturer's direc-
tions, and plasmid transfected cells were harvested at 24 hpt. Whole
cell lysates of virus-infected and plasmid transfected cells were separat-
ed by SDS-PAGE and then transferred to a nitrocellulose membrane
(Ambion) by using a semi-dry electroblotter and molecular weight
markers (Bio-Rad Laboratories). The immediate-early (IE), early (IR4,
EICP0, UL3, and UL5) and late (gD and ETIF) proteins were detected
by using anti-EHV-1 protein rabbit polyclonal antibodies (Bowles
et al., 1997; Caughman et al., 1995; Flowers and O'Callaghan, 1992;
Harty et al., 1993a; Holden et al., 1994; Lewis et al., 1997; Zhao et al.,
1995) as primary antibodies and an anti-rabbit IgG[Fc]-alkaline phos-
phatase conjugate (Promega) as a secondary antibody. Proteins were
visualized by incubating the membrane containing blotted proteins in
the AP conjugate substrate (AP conjugate substrate kit, Bio-Rad Labora-
tories) according to manufacturer's directions.
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growth kinetics
For plaque assays, 90% conﬂuent RK13 cells in 6 well plates were
infected with serial dilutions of RacL11, vL11ΔUL3, or vL11ΔUL3R.
After 1 hour attachment at 4 °C, virus-infected cells were covered with
medium containing 1.5% methylcellulose and incubated in 5% CO2 at
37 °C. At 4 dpi, plaques were ﬁxed with 10% formalin, stained with
0.5% crystal violet, and counted (Perdue et al., 1974). Plaque sizes of
RacL11, vL11ΔUL3 or vL11ΔUL3R were measured by using an ImageJ
software program (NIH, http://rsbweb.nih.gov/ij/). For single step
growth kinetics, 90% conﬂuent RK13 cells in 25 mm2ﬂaskwere infected
with RacL11, vL11ΔUL3 or vL11ΔUL3R at moi of 0.2 or 2. After 1 h of
viral attachment at 4 °C, virus-infected RK13 cells were washed with
PBS, and then 4 ml of growthmediumwas added. Cells and supernatant
were harvested at designated time points. Intracellular virus was re-
leased by a freeze and thaw cycle, and samples were titered as de-
scribed above. To determine the cell tropism of vL11ΔUL3, LM, RK13,
NBL-6, Vero, and HeLa cells were infected with RacL11, vL11ΔUL3 or
vL11ΔUL3R at moi of 5. After 1 h of virus attachment at 4 °C, virus-
infected cells werewashedwith PBS followed by adding normal growth
medium, and total viral titers were examined at 3 dpi.
Animal experiments and statistical analysis
Animal experiments were conducted as described previously (Ahn
et al., 2011; Charvat et al., 2011; Osterrieder et al., 1996; von Einem
et al., 2004). Groups (n=12 for mock infected, n=12 for vL11ΔUL3,
n=12 for vL11ΔUL3R, and n=12 for RacL11) of four-week-old CBA
mice were intranasally inoculated with 3×106 pfu of vL11ΔUL3,
vL11ΔULR, RacL11, or sterile medium as a mock infection. Mice were ob-
served daily for clinical signs and weighed from prior to inoculation until
7 days post infection. Isolation of virus from lungs of dead or livemicewas
performed by using silica Beads and a BeadBeater (BioSpec Products, Inc.,
Bartlesville, OK) according to the manufacturer's directions, followed by
viral titration as described above. Viruses were isolated from each group
of live mice infected with the RacL11 (n=3), vL11ΔUL3R (n=3), or
vL11ΔUL3 (n=3) at 2, 3 and 4 dpi, and virus isolation from lungs of the
dead mice was performed at the time of death. For the statistical analysis
to compare the body weight of mice between two groups and plaque
sizes of viruses, the two-tailed Student's t-test was performed by
using an excel software program (Microsoft Corporation, Redman,
WA). Signiﬁcance of the percent survival to judge virulence was deter-
mined by the Log-rank (Mantel–Cox) test using GraphPad Prism soft-
ware (GraphPad software, Inc., La Jolla, CA).
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